HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapse

DSpace/Manakin Repository

HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapse

Citable link to this page

 

 
Title: HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapse
Author: Coltella, Nadia; Percio, Stefano; Valsecchi, Roberta; Cuttano, Roberto; Guarnerio, Jlenia; Ponzoni, Maurilio; Pandolfi, Pier Paolo; Melillo, Giovanni; Pattini, Linda; Bernardi, Rosa

Note: Order does not necessarily reflect citation order of authors.

Citation: Coltella, Nadia, Stefano Percio, Roberta Valsecchi, Roberto Cuttano, Jlenia Guarnerio, Maurilio Ponzoni, Pier Paolo Pandolfi, Giovanni Melillo, Linda Pattini, and Rosa Bernardi. 2014. “HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapse.” EMBO Molecular Medicine 6 (5): 640-650. doi:10.1002/emmm.201303065. http://dx.doi.org/10.1002/emmm.201303065.
Full Text & Related Files:
Abstract: Acute promyelocytic leukemia (APL) is epitomized by the chromosomal translocation t(15;17) and the resulting oncogenic fusion protein PML-RARα. Although acting primarily as a transcriptional repressor, PML-RARα can also exert functions of transcriptional co-activation. Here, we find that PML-RARα stimulates transcription driven by HIF factors, which are critical regulators of adaptive responses to hypoxia and stem cell maintenance. Consistently, HIF-related gene signatures are upregulated in leukemic promyelocytes from APL patients compared to normal promyelocytes. Through in vitro and in vivo studies, we find that PML-RARα exploits a number of HIF-1α-regulated pro-leukemogenic functions that include cell migration, bone marrow (BM) neo-angiogenesis and self-renewal of APL blasts. Furthermore, HIF-1α levels increase upon treatment of APL cells with all-trans retinoic acid (ATRA). As a consequence, inhibiting HIF-1α in APL mouse models delays leukemia progression and exquisitely synergizes with ATRA to eliminate leukemia-initiating cells (LICs).
Published Version: doi:10.1002/emmm.201303065
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023886/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406959
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters